Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gini F Fleming

Showing results (61-70 of 180) with videos related to

Pageof 18
Sort By:
Gynecologic Oncology Reports|May 6, 2022
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomasKatherine C Kurnit, Meghan Steiner, Ricardo R Lastra, et al.
Springerplus|August 21, 2013
Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancerSumita S Bhatta, Ningqi Hou, Zakiya N Moton, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trialsJohnny Kao, Suzanne D Conzen, Nora T Jaskowiak, et al.
CA: a Cancer Journal for Clinicians|May 11, 2019
Current recommendations and recent progress in endometrial cancerRebecca A Brooks, Gini F Fleming, Ricardo R Lastra, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 14, 2024
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancerKun Lin, Elena Michaels, Eric Polley, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2018
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian CancerTatsuo Matsuda, Matthias Leisegang, Jae-Hyun Park, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
Gynecologic Oncology|May 1, 2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancerJennifer Taylor Veneris, Kathleen M Darcy, Paulette Mhawech-Fauceglia, et al.
Cancer|September 27, 2006
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group studyG Larry Maxwell, Chunqiao Tian, John Risinger, et al.
Pageof 18

Showing results (61-70 of 180) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology Reports|May 6, 2022
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomasKatherine C Kurnit, Meghan Steiner, Ricardo R Lastra, et al.
Springerplus|August 21, 2013
Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancerSumita S Bhatta, Ningqi Hou, Zakiya N Moton, et al.
International Journal of Radiation Oncology, Biology, Physics|March 9, 2005
Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trialsJohnny Kao, Suzanne D Conzen, Nora T Jaskowiak, et al.
CA: a Cancer Journal for Clinicians|May 11, 2019
Current recommendations and recent progress in endometrial cancerRebecca A Brooks, Gini F Fleming, Ricardo R Lastra, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 14, 2024
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancerKun Lin, Elena Michaels, Eric Polley, et al.
Gynecologic Oncology|June 10, 2020
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 studyErika Hamilton, David M O'Malley, Roisin O'Cearbhaill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2018
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian CancerTatsuo Matsuda, Matthias Leisegang, Jae-Hyun Park, et al.
Breast Cancer Research and Treatment|December 4, 2008
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumabAruna Mani, Julie Roda, Donn Young, et al.
Gynecologic Oncology|May 1, 2017
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancerJennifer Taylor Veneris, Kathleen M Darcy, Paulette Mhawech-Fauceglia, et al.
Cancer|September 27, 2006
Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group studyG Larry Maxwell, Chunqiao Tian, John Risinger, et al.
Pageof 18